Tocilizumab in COVID-19: some clarity amid controversy

[...]one of the concerns surrounding tocilizumab use in patients with COVID-19 is the risk of secondary infection, and although tocilizumab did not result in any deaths from secondary infection, the investigators did not collect data on non-fatal infections or other adverse events. [...]important ph...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 2021-05, Vol.397 (10285), p.1599-1601
Hauptverfasser:	Gupta, Shruti, Leaf, David E
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized Blood pressure Comment Coronaviruses COVID-19 COVID-19 Drug Treatment Data collection Hospitals Humans Immunosuppressive agents Infections Investigations Monoclonal antibodies Mortality Oxygen Partial pressure Proteins SARS-CoV-2 Secondary infection Severe acute respiratory syndrome coronavirus 2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!